Johnson & Johnson JNJ

$267.14 -5.56 (-2.04%)

Valuation

Market cap
656,473,472,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.17
P/E (forward)
25.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,842,200
Avg volume
7,466,768
Day's range
$264.68 – $270.60
Shares out
2,407,310,000
Stochastic %K
10%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

SellasGPS24BAT14 Nov 20, 2:44 PM
$ABBV $BMY $JNJ $PFE $SLS 0 FDA approved non toxic Cancer treatments. GPS will be the first off the shelf 0 Toxicity cancer drug ever. ✌️🙏❤️‍🩹
0 replies
Jamtrades Nov 20, 2:43 PM
$JNJ strong
0 replies
SellasGPS24BAT14 Nov 20, 2:39 PM
$SLS $JNJ $PFE $BMY $ABBV 300 Million cash on hand. Shares are locked up. Negotiation from position of strength with backing from biggest banks on the planet to get the deal done. ✌️🙏❤️‍🩹
0 replies
CasperPuff Nov 20, 2:26 PM
$JNJ safe haven
0 replies
AdamBrennan2 Nov 20, 12:26 PM
eton $ETON has burned cash for nine years and paid for it by issuing shares it sells rare disease drugs to pediatric endocrinologists through its own sales force. operating cash over the period is negative 35 million, and the share count is up 131.2% the money is going into manufacturing and the sales team for new launches either those launches grow into real cash flow, or this is a business that keeps asking shareholders to fund it $LLY $JNJ $AZN $NVO
0 replies
topstockalerts Nov 20, 12:21 PM
Pre Market Top Gainers PT2 $VRTX $WMT $JNJ $SNY $GILD
0 replies
MeiLingZhou Nov 20, 10:30 AM
$IBRX cant wait for the random $JNJ buyout now
4 replies
viji998 Nov 20, 5:28 AM
$NBIS every freaking $WMT $JNJ $JPM or take any sector depends on data , so data to be processed via AI models they need more and more capacity people who don’t have basic knowledge they just spread the rumors to make others to believe more like shorts 🩳
0 replies